Type 2 diabetes mellitus and hypertension Circulatory System Type 2 diabetes mellitus and hypertension
Conditions
Interventions
In this cross-over study, each participant was treated with two different drugs and a placebo, one at a time, in addition to his or her standard medication. Each drug / placebo treatment lasted for 4
Sponsors
Tenovus Scotland (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with type 2 diabetes mellitus and hypertension who were on standard treatment were recruited. All patients were on either Angiotensin Converting Enzyme (ACE) inhibitors or angiotensin receptor blockers.
Exclusion criteria
Exclusion criteria: 1. Blood pressure <140 mm Hg systolic and 80 mm Hg diastolic 2. Recent admission to hospital within last 4 weeks 3. History of alcohol abuse 4. Liver or renal impairment 5. Heart failure 6. On potassium sparing diuretics, insulin or warfarin (procedural risks)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in endothelial function, assessed 24 months after the start of the trial. | — |
Secondary
| Measure | Time frame |
|---|---|
| The following were assessed 24 months after the start of the trial: 1. Improvement in the other prognostic markers of PIIINP and B-type Natriuretic Peptide (BNP) 2. Improvement in heart rate variability | — |
Countries
United Kingdom
Outcome results
None listed